E. Ohman J or Asset Management AB Grows Position in Boston Scientific Corporation $BSX

E. Ohman J or Asset Management AB boosted its position in Boston Scientific Corporation (NYSE:BSX) by 5.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 593,165 shares of the medical equipment provider’s stock after acquiring an additional 28,694 shares during the quarter. Boston Scientific accounts for about 1.0% of E. Ohman J or Asset Management AB’s holdings, making the stock its 24th biggest holding. E. Ohman J or Asset Management AB’s holdings in Boston Scientific were worth $37,221,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Colonial Trust Co SC grew its stake in shares of Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares in the last quarter. Garton & Associates Financial Advisors LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth $26,000. Finally, Bangor Savings Bank increased its holdings in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 142 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Activity

In other Boston Scientific news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the transaction, the director owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Stock Up 0.0%

Boston Scientific stock opened at $45.30 on Friday. The company has a market capitalization of $67.33 billion, a P/E ratio of 18.95, a PEG ratio of 0.87 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a fifty-two week low of $44.44 and a fifty-two week high of $109.50. The stock has a 50-day simple moving average of $54.71 and a 200-day simple moving average of $73.03.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has approved a share repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Stifel Nicolaus set a $75.00 price objective on Boston Scientific in a research report on Wednesday, May 27th. Barclays dropped their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. UBS Group cut their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Finally, Leerink Partners lowered their price target on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $85.08.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.